An efficacy trial of the malaria vaccine SPf66 in Gambian infants—second year of follow-up

In 1994, 630 Gambian infants were immunized with three doses of the synthetic polypeptide malaria vaccine SPf66 or with a control vaccine. No significant protection against first or total attacks of malaria was observed among the children who received SPf66. However, the period of follow-up was shor...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 1998, Vol.16 (1), p.62-67
Main Authors: Bojang, K.A, Obaro, S.K, D'Alessandro, U, Bennett, S, Langerock, P, Targett, G.A.T, Greenwood, B.M
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Female
Follow-Up Studies
Fundamental and applied biological sciences. Psychology
Gambia
Humans
Infant
malaria
malaria vaccine
Malaria Vaccines - therapeutic use
Malaria, Falciparum - prevention & control
Male
Plasmodium falciparum
Protozoa
Protozoan Proteins
Recombinant Proteins
SPf66
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
Vaccines, Synthetic - therapeutic use
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In 1994, 630 Gambian infants were immunized with three doses of the synthetic polypeptide malaria vaccine SPf66 or with a control vaccine. No significant protection against first or total attacks of malaria was observed among the children who received SPf66. However, the period of follow-up was short. Thus, 532 children were followed for a second malaria transmission season during which 291 episodes of malaria were detected. Protective efficacies of SPf66 against first attacks of malaria and against all attacks of malaria were 8% [95% CI −20%, 30%] and 2% [95% CI −26% 24%] respectively. SPf66 did not provide any significant degree of protection to Gambian infants during a second year of follow-up.
ISSN:0264-410X
1873-2518
DOI:10.1016/S0264-410X(97)00159-X